Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of some unusual options trading on Wednesday. Stock investors bought 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the average volume of 53 put options.

Maravai LifeSciences Stock Performance

MRVI opened at $2.67 on Friday. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The stock’s 50 day moving average price is $4.64 and its two-hundred day moving average price is $6.32. The firm has a market capitalization of $674.25 million, a P/E ratio of -1.63 and a beta of -0.08. Maravai LifeSciences has a 12-month low of $2.65 and a 12-month high of $11.56.

Insider Buying and Selling at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the completion of the sale, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54. The trade was a 12.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Several hedge funds and other institutional investors have recently modified their holdings of MRVI. Performa Ltd US LLC raised its stake in Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after purchasing an additional 4,300 shares during the last quarter. FNY Investment Advisers LLC raised its position in shares of Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock valued at $38,000 after buying an additional 6,000 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Maravai LifeSciences in the third quarter valued at about $47,000. Farther Finance Advisors LLC grew its position in Maravai LifeSciences by 3,541.4% during the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock worth $56,000 after buying an additional 9,916 shares in the last quarter. Finally, Cibc World Markets Corp bought a new position in Maravai LifeSciences during the fourth quarter valued at about $56,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Analyst Upgrades and Downgrades

MRVI has been the subject of a number of analyst reports. William Blair reiterated a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. The Goldman Sachs Group cut shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $7.00 to $4.25 in a report on Thursday, December 5th. Bank of America cut their target price on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday. Wolfe Research began coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, Baird R W lowered Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Maravai LifeSciences currently has a consensus rating of “Hold” and an average price target of $9.28.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.